or Try an Advanced Search...

    Technical Analysis for CPH - Cipher Pharmaceuticals Inc.

    Grade Last Price % Change Price Change
    C 14.860 2.06% 0.300
    CPH closed up 2.06 percent on Friday, November 22, 2024, on 55 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical CPH trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Outside Day Range Expansion 0.00%
    Fell Below 20 DMA Bearish 2.06%
    Crossed Above 20 DMA Bullish 0.95%
    MACD Bullish Signal Line Cross Bullish 0.95%
    NR7 Range Contraction 0.95%
    NR7-2 Range Contraction 0.95%
    Narrow Range Bar Range Contraction 0.95%
    Up 3 Days in a Row Strength 0.95%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.43%
    Older End-of-Day Signals for CPH ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 19 hours ago
    Rose Above Previous Day's High about 19 hours ago
    Outside Day about 19 hours ago
    Up 1% about 21 hours ago
    Rose Above 20 DMA about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CPH Chart by TradingView
    Basic chart:

    Profile

    Cipher Pharmaceuticals Inc. Description

    Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Pipe Pharma Pipeline Pharmaceutical RTT Skin Pharmaceuticals IPO Organ Systems Arthritis Psoriasis Ulcer Dermatology Nail Rheumatoid Arthritis Acne Actinic Keratosis Herpes Labialis Keratosis Onychomycosis Plaque Psoriasis

    Is CPH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Cipher Pharmaceuticals' (TSE:CPH) Sluggish Earnings Might Be Just The Beginning Of Its Problems
    Nov 9 Cipher Pharmaceuticals Inc (CPHRF) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
    Nov 9 Cipher Pharmaceuticals Third Quarter 2024 Earnings: EPS Misses Expectations
    Nov 7 Cipher Pharmaceuticals Reports Third Quarter 2024 Results
    Nov 4 Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call
    Oct 25 Discovering Three Undiscovered Gems in Canada
    Oct 8 Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer
    Sep 24 Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver
    Sep 13 Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results
    Sep 13 Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
    See more CPH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 19.69
    52 Week Low 5.35
    Average Volume 80,395
    200-Day Moving Average 11.226
    50-Day Moving Average 15.277
    20-Day Moving Average 14.540
    10-Day Moving Average 13.906
    Average True Range 0.767
    RSI (14) 50.50
    ADX 20.49
    +DI 22.018
    -DI 25.649
    Chandelier Exit (Long, 3 ATRs) 14.510
    Chandelier Exit (Short, 3 ATRs) 14.830
    Upper Bollinger Bands 16.430
    Lower Bollinger Band 12.649
    Percent B (%b) 0.58
    BandWidth 26.003
    MACD Line -0.344
    MACD Signal Line -0.468
    MACD Histogram 0.124
    Fundamentals Value
    Market Cap 401.65 Million
    Num Shares 27 Million
    EPS 0.28
    Price-to-Earnings (P/E) Ratio 52.51
    Price-to-Sales 0.85
    Price-to-Book 0.55
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.850
    Resistance 3 (R3) 15.750 15.320 15.685
    Resistance 2 (R2) 15.320 15.068 15.370 15.630
    Resistance 1 (R1) 15.090 14.912 15.205 15.190 15.575
    Pivot Point 14.660 14.660 14.718 14.710 14.660
    Support 1 (S1) 14.430 14.408 14.545 14.530 14.145
    Support 2 (S2) 14.000 14.252 14.050 14.090
    Support 3 (S3) 13.770 14.000 14.035
    Support 4 (S4) 13.870